Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor Associated Antigen-specific EIE Cells Against Cancer
NCT03535246Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Engineered Immune Effector therapy in cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Started Jul 2025; status: terminated.
02
Drugs
Engineered Immune Effector therapy
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03535246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535246.